These observations suggest that genetic targeting of a MYC cofactor confers a significant survival benefit in a mouse model of PDAC and highlight the need to develop and test PAF1c inhibitors [74] for tumor therapy, particularly in tumors with deregulated MYC expression profiles. Here, MYC is linked to neoplasm.